🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT05870163
Recruiting Observational

Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment

NCT05870163 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2023-02-20
Last updated
2025-04-01

Condition(s) studied

Gastroesophageal Reflux Disease (GERD)

Investigational drug(s) / intervention(s)

RefluxStop implantationNissen fundoplication

RefluxStop implantation: Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use

Nissen fundoplication: Standard of care Nissen fundoplication surgery

Study summary

This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Willing and able to provide informed consent and to participate in the registry study, 2. Patient's age ≥ 18 years or according to local legal age of adulthood if older, 3. Documented GERD present for \> 6 months, 4. Patient has a 24-hour pH monitoring proven GERD with pH and/or impedance pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be \<4 for \>4.5% of time during a 24-hour monitoring and/or total reflux episodes of acid \>55 or weakly acid \>26 for \>5 seconds at 5 cm above LES) 5. Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator. Exclusion criteria: 1. Presence of para-esophageal hernia or sliding hernia \> 3 centimeters, 2. Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed, 3. History of bariatric surgery wherein the stomach fundus has been extirpated, 4. Female patients who are pregnant or nursing, 5. Known sensitivity or allergies to silicone materials, 6. Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry study procedure (as outlined in the IFU); 7. Patients that are unable to comply with the registry study requirements, (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the registry study according to the investigator's judgement).

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Klinikum Friedrichshafen GmbH Friedrichshafen Germany Active Not Recruiting
Ospedale IRCCS Saverio De Bellis Bari Italy Recruiting
Ospedale Buon Consiglio Fatebenefratelli Naples Italy Recruiting
Akershus Universitetssykehus HF Lørenskog Norway Recruiting
Inselspital, Universitätsspital Bern Bern Switzerland Recruiting
Hirslanden Klinik Bern Switzerland Recruiting

More Implantica CE Reflux Ltd. trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05870163 on ClinicalTrials.gov ↗ ← All trials in Germany